WASHINGTON (AP) — For Democrats demoralized at being shut out of power in Washington, the past several months have offered reason for optimism. But the U.S. and Israeli strikes against Iran could test ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. CSL has started construction ...

C SL has broken ground for an expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois. The newly expanded facility will substantially increase the global biopharma company’s ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Unity Software (NYSE:U) is expected to outline its upcoming technology roadmap ...

CSL shares rebound after hitting an 8-year low as brokers see a potential upside. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become ...

The CSL Ltd (ASX: CSL) share price is 2% higher at $145.71 a piece in Thursday morning trade. At the time of writing, the beaten-down biotech stock is down 15.24% year to date and 44.85% over the year ...

Attention, gamers: if you thought new titles on top of the endless cavalcade of sequels and remakes were derivative now, wait till you hear about what the game engine maker Unity has got in store.

Eli Lilly has been scouting for drugs to follow the trail blazed by its blockbuster cardiometabolic medicines. Its latest pipeline-building deal has the pharmaceutical company paying $100 million for ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

Unity stock has tumbled twice recently, first after Google's Project Genie Reveal, and then after a disappointing earnings report. Project Genie is impressive, but it won't replace video game engines.

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

SYDNEY--Shares of pharmaceutical company CSL fell early Wednesday as investors react to the sudden departure of chief executive Paul McKenzie and an 80% fall in first-half net profit. The stock was ...